|
TW202017942A
|
|
Anti-tnfα/anti-il-17a natural antibody structure-like heterodimeric bispecific antibody, and preparation method thereof
|
|
CN111712522A
|
|
anti-PD-1/anti-VEGF natural antibody structure-like heterodimer form bispecific antibody and preparation thereof
|
|
KR20200093639A
|
|
Anti-PD-L1/anti-CD47 bispecific antibody in the form of a natural antibody structure-like heterodimer and preparation thereof
|
|
KR20190139909A
|
|
Anti-PD-L1 / anti-PD-1 native antibody structure-like heterodimer bispecific antibodies and preparations thereof
|
|
WO2019153200A1
|
|
Anti-pd-1/anti-her2 natural antibody structure-like bispecific antibody in heterodimeric form and preparation thereof
|
|
KR20190065375A
|
|
Heterodimeric bispecific antibodies in the form of anti-PD-1 / anti-HER2 natural antibody constructs and methods for their production
|
|
CA3035681A1
|
|
Heterodimeric immunoglobulin constructs and preparation methods thereof
|
|
CN107446048A
|
|
A kind of antibody and its function fragment that can specifically combine PD 1
|
|
KR20180035919A
|
|
IRAK4 inhibitors and uses thereof
|
|
WO2016119641A1
|
|
N-benzoate group substituted benzopyrroline-2-one derivative and use thereof
|
|
CN107074976A
|
|
The recombination fusion protein of B7/CD28 and IL6/IL6R/GP130 signal paths is blocked simultaneously
|
|
WO2017024589A1
|
|
Irak4 inhibitor and use thereof
|
|
WO2015139621A1
|
|
4-heteroaryl substituted benzoic acid or benzamides compound
|
|
CN104926733A
|
|
Compound used as RORgamma conditioning agent
|
|
CN105982897A
|
|
Liquid preparation, and preparation method and application thereof
|
|
WO2015113494A1
|
|
Bifunctional fusion protein, preparation method therefor, and use thereof
|
|
CN104744592A
|
|
Anti-HER2-anti-CD3 scFv bispecific tetravalent antibody
|
|
WO2016090628A1
|
|
Oxyntomodulin (oxm) analogs, synthesis and use thereof
|
|
CN105708824A
|
|
Application of ambroxol hydrochloride liquid preparation
|
|
RU2650512C2
|
|
Compounding, which inhibites activity of btk and/or jak3 kinases
|
